<DOC>
	<DOCNO>NCT01121848</DOCNO>
	<brief_summary>Primary Objective : To demonstrate addition oxaliplatin 5-Fluorouracil ( 5-FU ) Leucovorin ( LV ) improve Progression-Free Survival ( PFS ) . Progression base RECIST ( Response Evaluation Criteria In Solid Tumors ) criteria death Secondary Objective : To evaluate measure tumor response , safety , quality life ( QoL ) , health utility assessment .</brief_summary>
	<brief_title>Randomized Study With Oxaliplatin 2nd Line Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Inclusion criterion : Histologically cytologically proven pancreatic carcinoma Measurable locally advance metastatic disease Patient previously treat 5FU `` radiation sensitizer '' toxicity must resolve Patients must receive Gemcitabinebased chemotherapy ( single agent combination ) 1st line therapy advance metastatic disease toxicity must resolve Patients receive last dose gemcitabine least 2 week prior randomization Confirmed radiographic disease progression ( Computed Tomogram ( CT ) scan Magnetic Resonance Imaging ( MRI ) within 4 week prior randomization Adequate liver kidney function : Total bilirubin inferior 1.5 Upper Limit Normal ( ULN ) Creatinine clearance ( ClCr ) superior 50 mL / min Aspartate Transferase ( AST ) inferior 3 ULN liver metastasis AST inferior 5 ULN liver metastasis Alanine Aminotransferase ( ALT ) inferior 3 ULN liver metastasis ALT inferior 5 ULN liver metastasis Adequate hematological function : Neutrophils superior egal 1.5 x 109/L Platelets superior egal 100 x 109/L Exclusion criterion : Peripheral sensory motor neuropathy &gt; grade 1 Eastern Cooperative Oncology Group ( ECOG ) Performance status &gt; 2 Serious cardiac arrhythmia , diabetes , serious active infection active illness would preclude study participation opinion investigator Pernicious anemia megaloblastic anemia vitamin B12 deficiency Previous ( great 5 year ) current malignancy origin within past 5 year Lack physical integrity upper gastrointestinal tract , clinically significant malabsorption syndrome , inability take oral medication History know allergy oxaliplatin platinum compound , 5FU , LV ingredient formulation container Severe renal impairment ( ClCr &lt; 50 mL/min ) Pregnant woman breastfeed Patients ( male female ) reproductive potential implementing accept effective method contraception ( definition `` effective method contraception '' base investigator ' judgment ) The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>